Recent Updates
Recently added Catalysts

Dyslipidemia: one US-listed biotech with a clinical-stage programme

Cardiovascular & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$3.1Buniverse median $1.20B
Allocated capital$1.0B$3.1B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank151/299crowding rank 165

Dyslipidemia is uncontested. NewAmsterdam Pharma (NAMS) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Obicetrapib in phase 3.

There is no public comparable to price it against. NAMS spreads its $3.1B market cap across 3 indications, so $1.0B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$1.0B of allocated capital sits in Dyslipidemia, ranking it 151st of 299 indications by the money committed to it.

Companies developing drugs for Dyslipidemia 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NAMSNewAmsterdam PharmaObicetrapibPhase 32$3.1BNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Dyslipidemia counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Dyslipidemia has one competitor and a median of $3.1B.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Atherosclerotic Cardiovascular Disease Management1 company · $1.0B · median $3.1BUncontestedLipid Metabolism Disorder1 company · $1.0B · median $3.1BUncontestedProteinuric Kidney Disease1 company · $719M · median $1.4BUncontestedChronic Kidney Disease Stage 3 and 41 company · $601M · median $1.2BUncontestedLong Chain Fatty Acid Oxidation Disorders1 company · $488M · median $1.5BUncontestedChronic Idiopathic Constipation1 company · $462M · median $924MUncontestedGestational Diabetes1 company · $424M · median $1.3BUncontestedHyperlipidemia1 company · $1.7B · median $12.2BUncontested

Dyslipidemia pipeline questions

Which biotech companies are developing drugs for Dyslipidemia?

NewAmsterdam Pharma (NAMS, Obicetrapib, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Dyslipidemia.

How advanced is the Dyslipidemia pipeline?

Of the 1 clinical-stage programme in Dyslipidemia, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Dyslipidemia?

No. NAMS is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Dyslipidemia, which is why the indication is classified as uncontested.

When is the next Dyslipidemia catalyst?

The next dated catalyst in Dyslipidemia is NAMS on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map